TY - JOUR
T1 - Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8 % topical patch
T2 - A case report
AU - Sayanlar, Jennifer
AU - Guleyupoglu, Nilufer
AU - Portenoy, Russell
AU - Ashina, Sait
N1 - Funding Information:
Conflict of interest Nulifer Guleyupoglu has served as a consultant for NeurogesX and Eli Lilly and Co. Russell K. Portenoy served as consultant for Arsenal Medical Inc., Pfizer, Grupo Ferrer, Transcept Pharma and Xenon. Russell K. Portenoy also received departmental educational/research grants from Allergan, Ameritox, Boston Scientific, Covidien Mallinckrodt Inc., Endo Pharmaceuticals, Forest Labs, K-Pax Pharmaceuticals, Medtronic, Otsuka Pharma, ProStrakan, Purdue Pharma, Salix and St. Jude Medical. Sait Ashina, MD, has served as a consultant for NeurogesX and Depomed.
PY - 2012/10
Y1 - 2012/10
N2 - Postherpetic neuralgia has been variably defined but is generally understood to be pain that persists for longer than a few months after an attack of herpes zoster. Pain persists for years in approximately 10 % of those afflicted with acute herpes zoster. The likelihood of postherpetic neuralgia increases with older age, severity of the zoster, trigeminal location, and other factors. Postherpetic neuralgia is a neuropathic pain and treatment usually involves sequential trials of topical and systemic drugs; a variety of other therapies may be considered in refractory cases. A new topical capsaicin 8 % patch has been approved for this indication based on the positive studies in patients with non-trigeminal postherpetic neuralgia. Experience with the use of the capsaicin 8 % patch for trigeminal distribution neuralgia is lacking. We report a case of trigeminal postherpetic neuralgia which was safely and effectively treated with capsaicin 8 % patch.
AB - Postherpetic neuralgia has been variably defined but is generally understood to be pain that persists for longer than a few months after an attack of herpes zoster. Pain persists for years in approximately 10 % of those afflicted with acute herpes zoster. The likelihood of postherpetic neuralgia increases with older age, severity of the zoster, trigeminal location, and other factors. Postherpetic neuralgia is a neuropathic pain and treatment usually involves sequential trials of topical and systemic drugs; a variety of other therapies may be considered in refractory cases. A new topical capsaicin 8 % patch has been approved for this indication based on the positive studies in patients with non-trigeminal postherpetic neuralgia. Experience with the use of the capsaicin 8 % patch for trigeminal distribution neuralgia is lacking. We report a case of trigeminal postherpetic neuralgia which was safely and effectively treated with capsaicin 8 % patch.
UR - http://www.scopus.com/inward/record.url?scp=84870352325&partnerID=8YFLogxK
U2 - 10.1007/s10194-012-0467-0
DO - 10.1007/s10194-012-0467-0
M3 - Article
C2 - 22717586
AN - SCOPUS:84870352325
SN - 1129-2369
VL - 13
SP - 587
EP - 589
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
IS - 7
ER -